Esophageal Diseases  >>  Cinqair (reslizumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cinqair (reslizumab) / Merck (MSD), UCB, Teva
NCT00635089: Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

Completed
3
190
US, Canada
reslizumab, Cinquil™, CEP-38072, CTx55700
Ception Therapeutics, Cephalon
Eosinophilic Esophagitis
01/12
01/12
NCT00538434: Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

Completed
2/3
227
US, Canada
Reslizumab, CTx55700, Cinquil™, CEP-38072, Saline
Ception Therapeutics
Eosinophilic Esophagitis
10/09
10/09

Download Options